Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jun 18 04:00PM ET
0.5023
Dollar change
+0.0523
Percentage change
11.62
%
Index- P/E- EPS (ttm)-1.22 Insider Own49.46% Shs Outstand41.79M Perf Week-16.73%
Market Cap20.99M Forward P/E- EPS next Y-0.66 Insider Trans0.00% Shs Float21.12M Perf Month164.09%
Income-50.77M PEG- EPS next Q-0.09 Inst Own8.10% Short Float3.29% Perf Quarter19.60%
Sales19.96M P/S1.05 EPS this Y50.00% Inst Trans-3.79% Short Ratio0.05 Perf Half Y24.09%
Book/sh-0.88 P/B- EPS next Y-2.33% ROA-113.13% Short Interest0.69M Perf Year-55.94%
Cash/sh0.19 P/C2.71 EPS next 5Y24.74% ROE-362.79% 52W Range0.14 - 1.90 Perf YTD19.94%
Dividend Est.- P/FCF- EPS past 5Y42.71% ROIC- 52W High-73.56% Beta1.69
Dividend TTM- Quick Ratio1.34 Sales past 5Y- Gross Margin83.98% 52W Low254.48% ATR (14)0.13
Dividend Ex-DateMar 08, 2023 Current Ratio1.34 EPS Y/Y TTM39.31% Oper. Margin-260.48% RSI (14)56.84 Volatility13.21% 39.47%
Employees46 Debt/Eq- Sales Y/Y TTM32.45% Profit Margin-254.28% Recom2.00 Target Price1.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q52.16% Payout- Rel Volume0.22 Prev Close0.45
Sales Surprise0.74% EPS Surprise-120.00% Sales Q/Q9.77% EarningsMay 08 Avg Volume13.39M Price0.50
SMA2052.76% SMA5098.78% SMA200-11.82% Trades Volume2,894,017 Change11.62%
Date Action Analyst Rating Change Price Target Change
Dec-12-24Downgrade Robert W. Baird Outperform → Neutral $10 → $1
Dec-10-24Downgrade BTIG Research Buy → Neutral
Apr-11-24Initiated BTIG Research Buy $6
Oct-03-23Initiated CapitalOne Overweight $10
Jul-06-23Initiated Evercore ISI Outperform $12
May-31-23Upgrade Jefferies Hold → Buy $0.60 → $7
May-24-23Initiated H.C. Wainwright Buy $10
Apr-14-23Initiated Robert W. Baird Outperform $10
Mar-31-25 04:30PM
Mar-26-25 08:00AM
Mar-19-25 05:15PM
Feb-19-25 07:30AM
Feb-05-25 07:30AM
08:30AM Loading…
Dec-09-24 08:30AM
Nov-27-24 07:30AM
Nov-17-24 07:30AM
Nov-08-24 07:30AM
Nov-07-24 07:30AM
Nov-05-24 09:05AM
Oct-30-24 04:30PM
Oct-04-24 09:05AM
Sep-10-24 07:30AM
Sep-03-24 07:30AM
12:00PM Loading…
Aug-13-24 12:00PM
Aug-08-24 09:00AM
07:30AM
Aug-06-24 07:30AM
07:30AM
Jul-01-24 07:30AM
Jun-28-24 07:39AM
Jun-27-24 04:30PM
Jun-26-24 06:53AM
Jun-25-24 07:30AM
07:30AM
Jun-13-24 04:30PM
May-30-24 07:30AM
May-16-24 07:30AM
May-09-24 01:54PM
08:35AM Loading…
08:35AM
07:30AM
May-08-24 07:30AM
May-06-24 07:30AM
May-02-24 10:01AM
07:30AM
Apr-24-24 05:05PM
Apr-22-24 04:35PM
Apr-04-24 09:55AM
Apr-03-24 07:00AM
Apr-01-24 01:53PM
08:35AM
07:00AM
Mar-21-24 05:00PM
Feb-28-24 07:30AM
Dec-21-23 07:00AM
Dec-14-23 07:00AM
Nov-28-23 07:00AM
Nov-22-23 07:30AM
Nov-09-23 07:30AM
Oct-31-23 09:25AM
Oct-25-23 09:11AM
Oct-12-23 02:52PM
Sep-05-23 08:30AM
Sep-01-23 08:30AM
Aug-24-23 08:30AM
Aug-23-23 09:55AM
Aug-13-23 08:07AM
Aug-10-23 07:30AM
Jul-19-23 06:34AM
Jun-28-23 08:30AM
Jun-26-23 08:30AM
Jun-14-23 08:30AM
Jun-08-23 01:11PM
Jun-05-23 07:30AM
May-30-23 04:30PM
May-11-23 07:30AM
May-08-23 04:30PM
May-05-23 04:30PM
Apr-14-23 12:51PM
Apr-06-23 04:30PM
Apr-04-23 08:30AM
Mar-20-23 02:04PM
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in April 2016 and is headquartered in Philadelphia, PA.